PharmaFocus Today

在勃林格殷格翰冷落之后,Nxera 正在寻找精神分裂症治疗项目买家

First innovative traditional Chinese medicine for frequent tension headaches launched.

The battle for rivaroxaban intensifies! Guilin Pharmaceutical enters the fray with its first generic dry suspension

Another biotech company goes bankrupt

Phase III Clinical Trial of Innovative Prostate Cancer Diagnostic Radiopharmaceutical TLX591-CDx Reaches Primary Endpoint in China

First Subject Dosed in Phase I Multiple Ascending Dose (MAD) Study of LAE102 for the Treatment of Obesity

CanSino’s DTcP-Hib-MCV4 Combination Vaccine Initiates Phase I Clinical Trial

Breakthrough Achieved in China’s Protein Subunit Vaccine Research “Our laboratory focuses on protein subunit vaccine research, and we have recently achieved a breakthrough. The structure of the COVID-19 RBD subunit vaccine can be extended to an octamer or hexamer, further enhancing its broad-spectrum efficacy,” stated Gao Fu, a pathologist, microbiologist, immunologist, and Academician of the Chinese Academy of Sciences, during the “Good Hope Science Salon” held on December 20. Gao Fu emphasized that the pandemic has accelerated fundamental research and industrialization in immunology and vaccinology, and that a deeper understanding of basic science can shorten the path from research to product development. “Understanding how influenza viruses enter cells via sialic acid receptors helps us develop drugs to block this process,” Gao Fu noted. By studying how viruses activate host immune responses, more effective vaccines can be designed to enhance the immune system’s ability to recognize and eliminate viruses. For a long time, insufficient vaccine efficacy has been one of the challenges facing the vaccine industry. Taking influenza vaccines as an example, the rapid mutation of respiratory viruses leads to lower-than-expected vaccine effectiveness. However, new technologies hold promise for changing this landscape. “We have developed multiple vaccine research and development strategies, including inactivated vaccines, live attenuated vaccines, protein subunit vaccines, viral vector vaccines, mRNA vaccines, multivalent combination vaccines, and virus-like particle vaccines,” Gao Fu explained. Gao Fu also highlighted that every biological outbreak is accompanied by the spread of misinformation, and these “information viruses” can be as harmful as the pathogens themselves. “This is why we advocate that ‘science communication is a social vaccine.’ Only by helping people understand scientific knowledge can we prevent the spread of rumors and collectively strengthen our defense against outbreaks,” he added. At the event, over 130 experts from academia, industry, and technology commercialization gathered to discuss the latest scientific achievements, pathways for transformation, and investment logic under the theme “The Path of Scientific Research

A new ADC champion has emerged.

Domestic ophthalmic monoclonal antibody achieves blockbuster BD

在勃林格殷格翰冷落之后,Nxera 正在寻找精神分裂症治疗项目买家

First innovative traditional Chinese medicine for frequent tension headaches launched.

The battle for rivaroxaban intensifies! Guilin Pharmaceutical enters the fray with its first generic dry suspension

Another biotech company goes bankrupt

Phase III Clinical Trial of Innovative Prostate Cancer Diagnostic Radiopharmaceutical TLX591-CDx Reaches Primary Endpoint in China

First Subject Dosed in Phase I Multiple Ascending Dose (MAD) Study of LAE102 for the Treatment of Obesity

CanSino’s DTcP-Hib-MCV4 Combination Vaccine Initiates Phase I Clinical Trial

A new ADC champion has emerged.

Domestic ophthalmic monoclonal antibody achieves blockbuster BD